NanoViricides Prepares for Critical Shareholders Meeting Amidst Rising MPox Concerns

NanoViricides, Inc., a leader in broad-spectrum antiviral drug development, has announced its Annual Shareholders Meeting for November 8, 2025, in Stamford, CT. The meeting comes at a crucial time as MPox Clade I cases emerge in California, raising potential public health concerns. President Anil R. Diwan underlined the importance of NV-387, which targets challenging viral strains, including MPox, COVID-19, and influenza.

NanoViricides is actively working on a Phase II clinical trial for NV-387's efficacy against MPox in the Democratic Republic of Congo. Notably, NV-387 has demonstrated promising safety in Phase I trials, differentiating it from other antiviral candidates like TPOXX and TEMBEXA, which face efficiency and safety scrutiny.

With standard treatments underperforming, Diwan emphasizes NV-387's pivotal role. As NanoViricides progresses towards clinical trials, the meeting will give vital insights into strategic directions against viral challenges.